Corrigendum to: Laccaic Acid A: A Natural Anthraquinone with Potent Anticancer Activity against MDA-MB-231 Cells.

In the originally published article [1], a line of text was inadvertently omitted under the "MTT Assay" and "Future Perspective" headings, and a portion of the subsequent paragraph was unintentionally truncated, resulting in the omission of sentences essential for the complete interpretation of the content. The original article can be found online at https://pubmed.ncbi.nlm.nih.gov/40192048/. Details of the error and a correction are provided below: ORIGINAL 3.4. MTT Assay To evaluate the anticancer activity of the four isolates against the MDA-MB-231 cell line, an MTT assay was performed. Adriamycin was used as the standard for comparison due to its well-established efficacy in breast cancer treatment. The percentage of cell inhibition was calculated based on the absorbance values presented in Table 4, with lower absorbance indicating higher cell exhibited moderate inhibition of cell proliferation, which significantly increased with higher doses. Among the isolates, Laccaic Acid A showed the highest activity, with an IC50 value less than 100 nM which is significantly lower CORRECTED 3.4. MTT Assay To evaluate the anticancer activity of the four isolates against the MDA-MB-231 cell line, an MTT assay was performed. Adriamycin was used as the standard for comparison due to its well-established efficacy in breast cancer treatment. The percentage of cell inhibition was calculated based on the absorbance values presented in Table 4, with lower absorbance indicating higher cell viability reduction. All isolates demonstrated promising anticancer activity in a dose-dependent manner, as depicted in Fig. (5). Specifically, at lower concentrations, the isolates exhibited moderate inhibition of cell proliferation, which significantly increased with higher doses. Among the isolates, Laccaic Acid A showed the highest activity, with an IC50 value less than 100 nM which is significantly lower than that of Adriamycin, highlighting its potent anticancer properties. The authors apologize for any inconvenience caused. ORIGINAL FUTURE PERSPECTIVES Future research should focus on in vivo studies to validate the therapeutic efficacy, safety, and pharmacokinetics of laccaic acids in animal models. Broader testing across various cancer cell lines, exploration of synergistic effects, and detailed molecular investigations of apoptotic pathways are essential. Developing advanced drug delivery systems to enhance bioavailability and studying structural derivatives to improve potency could further advance clinical translation. Ultimately, clinical trials will be necessary to establish their potential as CORRECTED FUTURE PERSPECTIVES Future research should focus on in vivo studies to validate the therapeutic efficacy, safety, and pharmacokinetics of laccaic acids in animal models. Broader testing across various cancer cell lines, exploration of synergistic effects, and detailed molecular investigations of apoptotic pathways are essential. Developing advanced drug delivery systems to enhance bioavailability and studying structural derivatives to improve potency could further advance clinical translation. Ultimately, clinical trials will be necessary to establish their potential as safe and effective anticancer agents for human use.